Interventional Oncology in Oligometastatic Disease: Closing the Treatment Gap

Metastasis-directed therapy (MDT) is currently an increasingly established component of oligometastatic disease (OMD) management. Interventional radiology (IR) offers a broad range of image-guided MDT options, including thermal ablation, nonthermal ablation, and transarterial therapies, yet remains structurally underutilized within multidisciplinary treatment pathways. As a result, IR-delivered therapies are often evaluated in late-referral or salvage contexts, producing comparative outcome data that are heavily influenced by selection bias and confounding by indication. Interpretation of the IR evidence base is further complicated by evidentiary lag, as many mature outcome data derive from earlier-generation technologies that may not fully reflect contemporary practice. This is particularly important because, in carefully selected patients and in the limited settings where randomized or well-controlled comparative data exist, IR-delivered therapies can achieve oncologic outcomes comparable with more invasive modalities while substantially reducing treatment morbidity, recovery time, hospital stay, and cost. MDT selection in OMD is inherently multidimensional: Durable local control must be weighed against treatment burden, repeatability, preservation of systemic therapy options, logistical feasibility, and patient preference. We summarize the evidence supporting IR-based MDT across hepatic, pulmonary, adrenal, nodal, osseous, and emerging neuro-oncologic OMD sites, with comparison with established surgical and radiotherapeutic approaches. We further propose a Pareto-based conceptual framework for patient-centered modality selection, in which multiple treatment strategies may represent efficient trade-offs rather than a single universally optimal approach. Interventional oncology should be viewed not as a salvage service but as an essential fourth pillar of cancer care alongside medical, surgical, and radiation oncology.

Authors

Institutions

Publication Details

Journal
JCO Oncology Practice
Published
2026-11-20
DOI
https://doi.org/10.1200/op-26-01000
Primary Topic
Management of metastatic bone disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Interventional Oncology in Oligometastatic Disease: Closing the Treatment Gap

Vamshi Krishna Kotha, Jan Grendar, Petra Grendarova, Olga Vornicova et al.
JCO Oncology Practice
Management of metastatic bone disease
article

Interventional Oncology in Oligometastatic Disease: Closing the Treatment Gap

Vamshi Krishna Kotha, Jan Grendar, Petra Grendarova, Olga Vornicova, Justin T. Blackman
article en

Abstract

Metastasis-directed therapy (MDT) is currently an increasingly established component of oligometastatic disease (OMD) management. Interventional radiology (IR) offers a broad range of image-guided MDT options, including thermal ablation, nonthermal ablation, and transarterial therapies, yet remains structurally underutilized within multidisciplinary treatment pathways. As a result, IR-delivered therapies are often evaluated in late-referral or salvage contexts, producing comparative outcome data that are heavily influenced by selection bias and confounding by indication. Interpretation of the IR evidence base is further complicated by evidentiary lag, as many mature outcome data derive from earlier-generation technologies that may not fully reflect contemporary practice. This is particularly important because, in carefully selected patients and in the limited settings where randomized or well-controlled comparative data exist, IR-delivered therapies can achieve oncologic outcomes comparable with more invasive modalities while substantially reducing treatment morbidity, recovery time, hospital stay, and cost. MDT selection in OMD is inherently multidimensional: Durable local control must be weighed against treatment burden, repeatability, preservation of systemic therapy options, logistical feasibility, and patient preference. We summarize the evidence supporting IR-based MDT across hepatic, pulmonary, adrenal, nodal, osseous, and emerging neuro-oncologic OMD sites, with comparison with established surgical and radiotherapeutic approaches. We further propose a Pareto-based conceptual framework for patient-centered modality selection, in which multiple treatment strategies may represent efficient trade-offs rather than a single universally optimal approach. Interventional oncology should be viewed not as a salvage service but as an essential fourth pillar of cancer care alongside medical, surgical, and radiation oncology.

JCO Oncology Practice
Island Health (CA), BC Cancer Agency (CA), University of British Columbia (CA), BC Cancer – Victoria (CA)
Good health and well-being
Management of metastatic bone disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon